Compassionate Use
Early Access Program: Access to innovative medicines for patients
A pharmaceutical company with a focus on clinical research has implemented a compassionate use program at the request of the medical profession.
Early Access Program: Access to innovative medicines for patients
A pharmaceutical company with a focus on clinical research implemented a compassionate use program at the request of the medical profession. We drew up the necessary contracts for this, tailored to the specific requirements of the intended treatment and the needs of the doctors involved. As a result, patients were able to benefit from a new treatment option at an early stage.
Experimental therapy
Swiss doctors have enquired with an international pharmaceutical company about the availability of a drug not approved in Switzerland for the treatment of a fatal disease as part of an experimental trial.
Swiss physicians contacted an international pharmaceutical company regarding the availability of a medicinal product not authorised in Switzerland for the treatment of a fatal disease. The product was intended for the treatment of a small number of patients for whom the available standard therapy was unsuitable or for whom all therapeutic options had been exhausted. We advised the company in order to enable the availability of the medicinal product in these cases.